Products - Multiple sclerosis | Topic | NICE

Showing 33 products

Date | Title

Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
28 May 2014
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
19 December 2019
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis (TA127)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 May 2024
Published:
22 August 2007
Multiple sclerosis in adults: management (NG220)
Product type:
Guidance
Programme:
NICE guideline
Published:
22 June 2022
Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 June 2022
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 June 2021
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 May 2021
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 November 2020
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 February 2020
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 June 2019
Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis (IPG640)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
30 January 2019
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 July 2018
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2018
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 August 2014
Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 June 2014
Published:
22 January 2014
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 April 2012
Functional electrical stimulation for drop foot of central neurological origin (IPG278)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 January 2009
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (IPG188)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 August 2006
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
29 March 2022
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
11 March 2016
Multiple sclerosis (QS108)
Product type:
Quality standard
Published:
14 January 2016
Cladribine for treating relapsing multiple sclerosis [ID6263]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 February 2025
Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
16 July 2025
Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Glatiramer acetate depot for multiple sclerosis [TS ID 10620]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis in people aged 13 to 17 TS ID 11778
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ublituximab for treating relapsing multiple sclerosis [ID6350]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tolebrutinib for treating relapsing multiple sclerosis ID6351
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evobrutinib for treating relapsing multiple sclerosis [ID6313]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis TS ID 11895
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC